

Number 559 • November 2015

Product supply shortage addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Sanis Health Inc., Ratiopharm and Sandoz Canada Inc. that the shortages of Bupropion SR 150 mg Sustained-Release Tablet (DIN 02391570), Ratio-Bupropion SR 150 mg Sustained-Release Tablet (DIN 02285665) and Sandoz-Bupropion SR 150 mg Sustained-Release Tablet (DIN 02275082) have been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping effective **December 7, 2015**:

BUPROPION HCL

150 MG ORAL SUSTAINED-RELEASE TABLET

00002391570	BUPROPION SR	SNS	\$ 0.2297
00002313421	PMS-BUPROPION SR	PMS	\$ 0.2297
00002285665	RATIO-BUPROPION SR	RPH	\$ 0.2297
00002275082	SANDOZ BUPROPION SR	SDZ	\$ 0.2297
00002237825	WELLBUTRIN SR	VCL	\$ 0.9768

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)



*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. ABC 82320.559 2015/11